veeto
Home
Bills
Influence
Feedback
hamburger
    Privacy PolicyResources
    © 2025 Veeto.
    AB-1320
    Health & Public Health

    California Affordable Drug Manufacturing Act of 2020: opioid antagonists.

    Introduced
    CA
    ∙
    2025-2026 Regular Session
    0
    0
    Track
    Track

    Key Takeaways

    • Prohibits state agencies from awarding no-bid contracts for overdose medications to opioid settlement companies.
    • Voids existing and future contracts that violate these restrictions, including those made before January 2026.
    • Applies specifically to naloxone and other FDA-approved drugs that counteract opioid overdoses.

    Summary

    Assembly Member Patterson's legislation aims to modify California's prescription drug procurement practices by prohibiting state agencies from awarding noncompetitive contracts for opioid antagonists to manufacturers who have entered into multistate opioid crisis settlements. The measure would add new restrictions to the California Affordable Drug Manufacturing Act of 2020, which currently allows state health agencies to enter into both exclusive and nonexclusive pharmaceutical purchasing agreements.

    The bill establishes specific parameters around the procurement of naloxone hydrochloride and other FDA-approved opioid overdose treatments. Under the proposed changes, any contracts for these medications must use competitive bidding processes if the potential supplier has previously settled multistate litigation related to their role in the opioid epidemic. The provisions would apply retroactively to agreements predating January 1, 2026, with non-compliant contracts becoming void and unenforceable.

    This modification to state purchasing authority creates new requirements for how California agencies acquire vital overdose prevention medications. While the existing law exempts certain pharmaceutical contracts from standard competitive bidding procedures, this measure carves out opioid antagonists for additional scrutiny when involving manufacturers with settlement histories. The bill maintains the broader framework of the 2020 Act while introducing targeted oversight for this specific category of life-saving drugs.

    Key Dates

    Next Step
    Referred to the Assembly Standing Committee on Health
    Next Step
    Assembly Committee
    Referred to the Assembly Standing Committee on Health
    Hearing has not been scheduled yet
    Assembly Health Hearing
    Assembly Committee
    Assembly Health Hearing
    Do pass and be re-referred to the Committee on [Appropriations]
    Assembly Health Hearing
    Assembly Committee
    Assembly Health Hearing
    Reconsideration
    Introduced
    Assembly Floor
    Introduced
    Introduced. To print.

    Contacts

    Profile
    Cecilia Aguiar-CurryD
    Assemblymember
    Committee Member
    Not Contacted
    Not Contacted
    Profile
    Heath FloraR
    Assemblymember
    Committee Member
    Not Contacted
    Not Contacted
    Profile
    Joaquin ArambulaD
    Assemblymember
    Committee Member
    Not Contacted
    Not Contacted
    Profile
    Mia BontaD
    Assemblymember
    Committee Member
    Not Contacted
    Not Contacted
    Profile
    Dawn AddisD
    Assemblymember
    Committee Member
    Not Contacted
    Not Contacted
    0 of 16 row(s) selected.
    Page 1 of 4
    Select All Legislators
    Profile
    Cecilia Aguiar-CurryD
    Assemblymember
    Committee Member
    Profile
    Heath FloraR
    Assemblymember
    Committee Member
    Profile
    Joaquin ArambulaD
    Assemblymember
    Committee Member
    Profile
    Mia BontaD
    Assemblymember
    Committee Member
    Profile
    Dawn AddisD
    Assemblymember
    Committee Member
    Profile
    Joe PattersonR
    Assemblymember
    Bill Author
    Profile
    Juan CarrilloD
    Assemblymember
    Committee Member
    Profile
    Kate SanchezR
    Assemblymember
    Committee Member
    Profile
    Pilar SchiavoD
    Assemblymember
    Committee Member
    Profile
    Mark GonzalezD
    Assemblymember
    Committee Member
    Profile
    Maggy KrellD
    Assemblymember
    Committee Member
    Profile
    Darshana PatelD
    Assemblymember
    Committee Member
    Profile
    Celeste RodriguezD
    Assemblymember
    Committee Member
    Profile
    LaShae Sharp-CollinsD
    Assemblymember
    Committee Member
    Profile
    Catherine StefaniD
    Assemblymember
    Committee Member
    Profile
    David TangipaR
    Assemblymember
    Committee Member

    Get Involved

    Act Now!

    Email the authors or create an email template to send to all relevant legislators.

    Introduced By

    Joe Patterson
    Joe PattersonR
    California State Assembly Member
    10% progression
    Bill has been formally introduced and read for the first time in its house of origin (2/21/2025)

    Latest Voting History

    View History
    April 29, 2025
    PASS
    Assembly Committee
    Assembly Health Hearing
    AyesNoesNVRTotalResult
    160016PASS

    Key Takeaways

    • Prohibits state agencies from awarding no-bid contracts for overdose medications to opioid settlement companies.
    • Voids existing and future contracts that violate these restrictions, including those made before January 2026.
    • Applies specifically to naloxone and other FDA-approved drugs that counteract opioid overdoses.

    Get Involved

    Act Now!

    Email the authors or create an email template to send to all relevant legislators.

    Introduced By

    Joe Patterson
    Joe PattersonR
    California State Assembly Member

    Summary

    Assembly Member Patterson's legislation aims to modify California's prescription drug procurement practices by prohibiting state agencies from awarding noncompetitive contracts for opioid antagonists to manufacturers who have entered into multistate opioid crisis settlements. The measure would add new restrictions to the California Affordable Drug Manufacturing Act of 2020, which currently allows state health agencies to enter into both exclusive and nonexclusive pharmaceutical purchasing agreements.

    The bill establishes specific parameters around the procurement of naloxone hydrochloride and other FDA-approved opioid overdose treatments. Under the proposed changes, any contracts for these medications must use competitive bidding processes if the potential supplier has previously settled multistate litigation related to their role in the opioid epidemic. The provisions would apply retroactively to agreements predating January 1, 2026, with non-compliant contracts becoming void and unenforceable.

    This modification to state purchasing authority creates new requirements for how California agencies acquire vital overdose prevention medications. While the existing law exempts certain pharmaceutical contracts from standard competitive bidding procedures, this measure carves out opioid antagonists for additional scrutiny when involving manufacturers with settlement histories. The bill maintains the broader framework of the 2020 Act while introducing targeted oversight for this specific category of life-saving drugs.

    10% progression
    Bill has been formally introduced and read for the first time in its house of origin (2/21/2025)

    Key Dates

    Next Step
    Referred to the Assembly Standing Committee on Health
    Next Step
    Assembly Committee
    Referred to the Assembly Standing Committee on Health
    Hearing has not been scheduled yet
    Assembly Health Hearing
    Assembly Committee
    Assembly Health Hearing
    Do pass and be re-referred to the Committee on [Appropriations]
    Assembly Health Hearing
    Assembly Committee
    Assembly Health Hearing
    Reconsideration
    Introduced
    Assembly Floor
    Introduced
    Introduced. To print.

    Latest Voting History

    View History
    April 29, 2025
    PASS
    Assembly Committee
    Assembly Health Hearing
    AyesNoesNVRTotalResult
    160016PASS

    Contacts

    Profile
    Cecilia Aguiar-CurryD
    Assemblymember
    Committee Member
    Not Contacted
    Not Contacted
    Profile
    Heath FloraR
    Assemblymember
    Committee Member
    Not Contacted
    Not Contacted
    Profile
    Joaquin ArambulaD
    Assemblymember
    Committee Member
    Not Contacted
    Not Contacted
    Profile
    Mia BontaD
    Assemblymember
    Committee Member
    Not Contacted
    Not Contacted
    Profile
    Dawn AddisD
    Assemblymember
    Committee Member
    Not Contacted
    Not Contacted
    0 of 16 row(s) selected.
    Page 1 of 4
    Select All Legislators
    Profile
    Cecilia Aguiar-CurryD
    Assemblymember
    Committee Member
    Profile
    Heath FloraR
    Assemblymember
    Committee Member
    Profile
    Joaquin ArambulaD
    Assemblymember
    Committee Member
    Profile
    Mia BontaD
    Assemblymember
    Committee Member
    Profile
    Dawn AddisD
    Assemblymember
    Committee Member
    Profile
    Joe PattersonR
    Assemblymember
    Bill Author
    Profile
    Juan CarrilloD
    Assemblymember
    Committee Member
    Profile
    Kate SanchezR
    Assemblymember
    Committee Member
    Profile
    Pilar SchiavoD
    Assemblymember
    Committee Member
    Profile
    Mark GonzalezD
    Assemblymember
    Committee Member
    Profile
    Maggy KrellD
    Assemblymember
    Committee Member
    Profile
    Darshana PatelD
    Assemblymember
    Committee Member
    Profile
    Celeste RodriguezD
    Assemblymember
    Committee Member
    Profile
    LaShae Sharp-CollinsD
    Assemblymember
    Committee Member
    Profile
    Catherine StefaniD
    Assemblymember
    Committee Member
    Profile
    David TangipaR
    Assemblymember
    Committee Member